ArticleScientific reports2025
Cardamonin inhibits the growth and stemness of osteosarcoma stem cells by inducing autophagy and inhibiting the Wnt/β-catenin signaling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cardamonin (CDN) has been shown to have promising anticancer effects against osteosarcoma (OS). Nevertheless, the molecular processes of it are still not well understood. Our investigation revealed that CDN has significant cytotoxic effects and diminishes cell viability in OS. The self-renewal ability was assessed using a sphere formation test, and the presence of marker proteins associated with cancer stem cells (CD133, SOX2, Nanog, and Oct4) was determined using Western blotting. These findings suggest that CDN significantly inhibits cancer stem cells (CSCs). Autophagy-related proteins (LC3, SQSTM1, Beclin1, and Atg5) were quantified via Western blotting, and the number of endogenous LC3 puncta was quantified via mRFP-GFP-LC3B adenovirus transfection. These outcomes manifest that CDN raises autophagy. The inhibition of autophagy with chloroquine (CQ) worsened the adverse effect of CDN on cancer stem cell stemness. This shows that CDN-induced autophagy inhibited the growth of osteosarcoma stem cells. The weakening of CSCs' ability to maintain their stemness in OS is achieved by blocking the Wnt/β-catenin (WBC) signaling pathway via the action of CDN. Moreover, CDN induces autophagy, which has a negative regulatory effect on the WBC signaling pathway. Conversely, the WBC signaling pathway can also regulate autophagy induced by CDN. Ultimately, the antitumor activity of CDN was verified via in vivo experiments in an OS xenograft model. Immunohistochemical analysis revealed that CDN upregulated LC3 expression and decreased CD133 and β-catenin expression, aligned with the findings of the in vitro experiments. Overall, this study establishes an empirical basis for using CDN as a therapeutic medication that specifically targets CSCs in treating OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.